label the everybody. final Ocaliva update. I'll discussing The label begin you, we by nearly and plan morning, is and shortly. Thank process our complete, good Jerry, communicate to
the expect well patients as in compensated in Portal who cirrhosis, with use hypertension. will as label have with patients We evidence decompensated final those of restrict cirrhosis, to
with a natural stable wide the clinically population. believe those these patients only assessment NISS to patients of with from demonstrate the safety updates shared As in cirrhosis to We identified disease cirrhosis, delineate is spectrum is from newly updates safety during disease. associated the focus will to who event eligible or the signal From with and of key a label reach compensated the comprehensive patients our the Ocaliva you FDA a discussions, result safety and most year, PBC process and advanced began monitoring liver in the severity is progression of of FDA PBC. know into often to prescribers implications enable are earlier medicine and a pathophysiologic PBC label. post-marketing findings for on of have from as for perspective, with we line previous development Ocaliva second Ocaliva; approach of with who working NISS, The XXXX. disorder. This liver identified update disease. broader approved identification was translate on and clear consequences agency not this from hypertension routine along been serious disease a advanced of this label Portal stages the end-stage Patients PBC decompensated These this patient
But XXX, a discussions the these to modifications final our continue about potential to The our defining a and requirements. beyond need the the studies discuss given study, post-marketing will forward path we study to update with FDA in for the we with updates align Regarding the and expect studies process and role FDA COBALT EMA. label continue will that EMA. label Ocaliva both post-approval of play
let's program. our Now to NASH turn development
working and dependencies recent previously a on alignment process, the resubmission. we've stated, which each As that and a of a interactions step-by-step that alignment preparation. towards potential require prior including with the agency, with data, of right data, FDA subsequent multiple the We're formal in key upcoming interpretation to significant
align items a to need our approval are on to the there resubmission prior that accelerated we pathway. with key FDA believe we reminder, a As potential of through three NDA
population, First, discuss profile update which be a a data with shared comprehensive the safety NASH amount will in safety refresh understanding fibrosis supported by FDA. safety and to increase to of OCA of the
field and profile importantly, methodology, for topic regulators, improve and data to the OCA of lastly, work additional an the accuracy. support fibrosis. in reading benefit And leaders better biopsy important industry, what beneficial will new if Second, any risk NASH and reduce establish efficacy as to thought to variability approaches be
interactions update these primarily three Let on of where FDA We've each with recent had items. me we're focused an on safety. provide
there's focus will and preparations the liver for first advancing While including additional insight exposure underway. areas updates key on that agency, safety double these our of also from safety elements submissions. have work deeper safety other safety the for the provided We're profile, our OCA
rigorous learnings data. to methodology, grounded furthering is to that months public the looking in biopsy approach believe Regarding has own to new we biopsy FDA a coming in We're and forward on applying and discussions approach methodology, scientifically led both biopsy FDA's statements our latest from us in the subsequently with on thinking methodology the REGENERATE and the that proposed field.
meetings also planned. the assess potential on of NASH OCA datasets additional fibrosis. progress with for made Again, have the regarding this We are topic of patients generation of treatment efficacy to FDA
For the patients XX-month result which resubmission. REGENERATE gathered additional were part of study these population following of enrolling additional approximately as potential design, from interim the a point. included XXX time in later of expect intensive biopsies, once a now XX-month analysis, include example, the they reach patients a treat We biopsies group the XX-month to any XXX as
is other time of the part analysis. To relevant of this continue by and for analysis in the their REGENERATE who context, we interim that Given inclusion study; XX-month put middle all and have were datasets ongoing patients to assess XX-month data to accrue this the will points. an year, reached
events Importantly, occur. the when the of study, REGENERATE meaning event-driven outcomes pre-specified trial is a number study that an completes
difficult exact the completion timing such is to predict. of As
As we've previously potential our latest our is estimates date away XXXX. point years and likely in completion a date to completion some stated,
REVERSE high from FDA compensated NASH very population, a our need. group at prepare with large pivotal will take in to with in advantage on have Phase for learnings We NASH. underway this important second with the methodology REVERSE as also to compensated X unmet believe data align we year. We study cirrhosis of to the due biopsy We of provide cirrhosis readout the a of top-line end patients plan NASH our patients work
our progress We also on pipeline. continue to make
PBC still IND the Our number combination X timeline trial approach when U.S. data complete. COVID-XX. does benefit supporting an combination disease patients, require clinical is the the is high an time may Phase of for bezafibrate bezafibrate with estimated and reinforce and in to OCA enrolling plus the currently now published for U.S. potential are but OCA. trial encouraging the in in open Enrollment and synergistic more take of due have not We'll we rare a outside provide trial a the Recently enrollment profile
to process later to further turn year. back agonist, call INT-XXX, turning underway. additional Finally, Jerry? the I'll now we We'll provide initiate FXR plan this study once updates our for next-generation Jerry a remarks. to over first-in-human is this
